Why Aurora Cannabis (TSX:ACB) Is Defying Gravity Today

Here’s why Aurora Cannabis (TSX:ACB)(NYSE:ACB) stock surged by nearly 7% Tuesday, despite its worse-than-expected Q4 results.

| More on:
edit Jars of marijuana

Image source: Getty Images

What happened?

Aurora Cannabis (TSX:ACB)(NYSE:ACB) stock price popped by nearly 7% to $8.65 per share today, despite the broader market weakness. By comparison, the TSX Composite Index was trading with 1.5% losses for the day due to a sharp selloff across sectors — especially in the tech sector. Interestingly, Aurora Cannabis announced its much worse-than-expected Q4 earnings yesterday.

Let’s find out what could be helping ACB stock defy gravity today, despite its dismal quarterly results.

So what?

Aurora Cannabis is a well-known Canadian cannabis company that primarily focuses on medical cannabis products. It currently has a market cap of about $1.6 billion. In the June quarter, its adjusted total revenue fell by nearly 20% YoY (year over year) to $54.8 million — missing analysts’ expectations of $56.3 million by a narrow margin. The company attributed its weaker revenue to lower consumer cannabis demand amid COVID-19-driven lockdown restrictions during the quarter. On the positive side, continued growth in Aurora’s international medical business boosted its medical segment revenue by about 9% YoY.

During its Q4 earnings conference call, Aurora Cannabis CEO Miguel Martin made positive comments about the EBITDA profitability. He indicated that the company could reach EBITDA profitability by the first half of the next fiscal year, even if its revenues don’t grow from its Q4 2021 levels. His positive comment could be responsible for boosting investors’ confidence and driving ACB stock higher today.

Now what?

Earlier today, analysts at MKM Partners upgraded their rating on Aurora Cannabis stock to “neutral” from “sell” and raised its fair value from $6 per share to $7 per share. This upgrade could be another reason why ACB stock price rallied by nearly 7% Tuesday.

While I don’t doubt Aurora’s EBITDA profitability prospects, its gross contracting gross margin amid declining consumer cannabis demand could be a reason of concern. That’s why I would recommend long-term investors to keep an eye on its demand and financial growth in the coming quarters before buying its stock.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool has no position in any of the stocks mentioned. Fool contributor Jitendra Parashar has no position in any of the stocks mentioned.

More on Cannabis Stocks